SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and com...
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy p...
March 2023: CAR-T-cell therapy is a novel and effective cancer treatment modality that has revolutionized the treatment of cancer, particularly blood cancers. This therapy achieves a therapeutic eff...
March 2023: Several types of lymphoma, as well as certain leukaemias and multiple myeloma, can now be effectively treated with CAR-T therapy. Recent studies have demonstrated the efficacy of CAR-T th...
Feb 2024: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a "renaissance" for lupus, according to a speaker at the symposium Basic and Cl...
Press Release Feb 2023: - Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical...
In February 2023, a phase 1 trial at a single institution found that it was safe and possible for people with heavily pretreated large B-cell lymphoma (LBCL) to use CD22-directed chimeric antigen rec...
Feb 2023: In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for triple-class exposed multiple myeloma. Abecma (idecabtagene vicleuc...
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prio...
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple...